Sign In | Create an Account | Welcome, . My Account | Logout | Subscribe | Submit News | Affiliated Sites | All Access E-Edition | Home RSS
 
 
 

Merck: FDA wants more studies of insomnia drug

Government expresses worries about patient safety

July 2, 2013
LINDA A. JOHNSON , AP Business Writer

TRENTON, N.J. - Drugmaker Merck & Co. said Monday that federal regulators have ruled they won't approve high doses of its experimental insomnia medication due to concerns about patient safety. However, the Food and Drug Administration indicated it would approve lower doses of the drug, suvorexant, after Merck does some new studies.

 
 
 

 

I am looking for:
in:
News, Blogs & Events Web